Global Blood Cancer Drugs Market Share Report 2024, Forecast To 2033
9 Jan, 2024
The blood cancer drugs market has exhibited strong growth, increasing from $69.16 billion in 2023 to $74.77 billion in 2024, achieving an 8.1% CAGR. Historical growth is attributed to advancements in research and development, an aging population, increased awareness, early diagnosis, and regulatory approvals. Future growth is anticipated, with the market poised to reach $100.9 billion by 2028, sustaining a 7.8% CAGR. Drivers for this growth include increasing disease prevalence, emerging markets, and supportive care. Major trends encompass research and development investments, combination therapies, biomarker identification, immunotherapy advancements, and personalized medicine.
Global Blood Cancer Drugs Market Key Driver
The blood cancer drugs market is propelled by a rise in death incidences and the global prevalence of blood cancer cases. Different types, like lymphoma and leukemia, have varying risk factors controlled or prevented through drug therapies. Bristol-Myers Squibb Company predicts over 1.85 million new blood cancer cases by 2040, with 1,100,000 estimated deaths. The growing number of deaths and cases globally is a driving force behind the blood cancer drug market.
Get A Free Sample Of The Global Blood Cancer Drugs Market ReportGlobal Blood Cancer Drugs Market Segments
The blood cancer drugs market covered in this report is segmented –
1) By Blood Cancer Type: Leukemia, Lymphoma
2) By Drugs: Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Other Drugs
3) By Treatment Approaches: Key Findings, Chemotherapeutic, mAbs/Targeted Therapies, Immunotherapeutic
By Geography: The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the blood cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Blood Cancer Drugs Industry Players
Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Roche Holding AG, Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Regeneron Pharmaceuticals Inc., Seattle Genetics Inc., Servier Laboratories, Shire plc, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A., Vertex Pharmaceuticals Incorporated
Get The Full Global Blood Cancer Drugs Market Report
Blood Cancer Drugs Market Overview
Blood Cancer Drugs Blood cancer drugs refer to the drugs or medications that are used to treat blood cancer drugs by using the body's immune system to fight blood cancer by slowing down the growth of cancer cells. Chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant are a few of the frequently used blood cancer treatments.
Blood Cancer Drugs Global Market Report 2023 provides data on the global blood cancer drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The blood cancer drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.